Antibody to liver-specific lipoprotein in acute and chronic liver diseases. its quantitative assay with monoclonal antibody, but without the use of liver-specific lipoprotein

Gastroenterologia Japonica volume 20, pages216–221(1985)Cite this article

Summary

A double-antibody radioimmunoassay was developed to detect antibody to human liver-specific membrane lipoprotein (anti-LSP antibody) in patients’ serum. Anti-human LSP monoclonal antibody was labeled with125I and anti-anti-LSP antiserum raised in rabbits was used as the first antibody in the assay. Anti-LSP antibody level was quantitatively measured and the assay was shown to be specific. Anti-LSP antibody was found in 5/8 patients with type B acute viral hepatitis (AVH), 3/7 patients with type A AVH, 1/6 patients with non-A, non-B AVH, 10/17 patients with chronic active hepatitis (CAH), 6/16 patients with chronic persistent hepatitis, 13/16 patients with active cirrhosis of the liver and 7/19 patients with primary nonhepatic autoimmune diseases such as glomerulonephritis, systemic lupus erythematosus and rheumatoid arthritis. The mean levels of anti-LSP were increased in patients with cirrhosis of the liver (p<0.01), CAH (p<0.05) and AVH (p<0.05) when compared with that of normal individuals. However, the frequencies of anti-LSP did not depend on HBsAg status. The data showed that anti-LSP antibody can be detected without the use of LSP preparation although it is also found in patients with primary nonhepatic autoimmune diseases.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

US$ 39.95

Tax calculation will be finalised during checkout.

References

  1. 1)

    Jensen DM, et al: Detection of autoantibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med 229: 1, 1978

    Article  Google Scholar 

  2. 2)

    Kakumu S, et al: Occurrence and significance of antibody to liver-specific membrane lipoprotein by double-antibody immunoprecipitation method in sera of patients with acute and chronic liver diseases. Gastroenterology 76: 665, 1979

    PubMed  CAS  Google Scholar 

  3. 3)

    Manns M, et al: Autoantibodies against liver-specific membrance lipoprotein in acute and chronic liver diseases: Studies on organ-, species-, and diseasespecificity. Gut21: 995, 1980

    Article  Google Scholar 

  4. 4)

    Miller J, et al: Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet2: 296, 1972

    PubMed  Article  CAS  Google Scholar 

  5. 5)

    Thomson AD, et al: Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature 252:721, 1974

    PubMed  Article  CAS  Google Scholar 

  6. 6)

    Meyer zum Büschenfelde KH, et al: Liver specific antigens. Purification and characterization. Clin exp Immunol 10: 89, 1972

    PubMed  Google Scholar 

  7. 7)

    Kawanishi H, et al: K-cell mediated antibody dependent cellular cytotoxicity in chronic active liver diseases. Gastroenterology 76: 151, 1979

    PubMed  CAS  Google Scholar 

  8. 8)

    Behrens UJ, et al: Studies on ‘liver-specific antigens.’ I. Evaluation of the liver specificity of ‘LSP and LP2.’ Gastroenterology 77: 1045, 1979

    PubMed  CAS  Google Scholar 

  9. 9)

    Chisari FV: Liver-specific protein in perscective. Gastroenterology 78: 168, 1980

    PubMed  CAS  Google Scholar 

  10. 10)

    Lebwohl N, et al: Characterization and demonstration of human liver-specific lipoprotein (LSP) and apo-LSP. Clin exp Immunol 46: 435, 1981

    PubMed  CAS  Google Scholar 

  11. 11)

    Murakami H, et al: The specificity of human liver membrane lipoprotein: Studies with monoclonal antibodies. Hepatology 4: 192, 1984

    PubMed  CAS  Article  Google Scholar 

  12. 12)

    Leevy CM, et al: Diseases of the Liver and Biliary Tracts: Standardization of Nomenclature, Diagnostic Criteria and Diagnostic Methodology. Castle House Publications Ltd, London(1979)

    Google Scholar 

  13. 13)

    Chisari FV, et al: Functional properties of lymphocyte subpopulations in hepatitis B virus infection. II. Cytotoxic effector cell killing of target that naturally express hepatitis B surface antigen and liver-specific lipoprotein. J Immunol 126: 45, 1981

    PubMed  CAS  Google Scholar 

  14. 14)

    Meliconi R, et al: Antibodies against human liverspecific protein (LSP) in acute and chronic viral hepatitis types A, B and non-A, non-B. Clin exp Immunol 46: 382, 1981

    PubMed  CAS  Google Scholar 

  15. 15)

    Gerber AM, et al: Liver-specific protein: How specific is it? in “Frontiers in Liver Disease” by Berk PD, Chalmers TC. Thieme-Stratton, New York, 1981, p 139

    Google Scholar 

  16. 16)

    McFarlane IG, et al: Development of a micro enzymelinked immunosorbent assay for antibodies against liver-specific membrane lipoprotein. J Immunol Methods 64: 215, 1983

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Third Department of Medicine, Nagoya University School of Medicine, 65 Tsuruma-cho, 466, Showa-ku, Nagoya, Japan

    Shinichi Kakumu M.D., Kentaro Yoshioka M.D. & Akinori Tsubouchi M.D.

Authors
  1. Shinichi Kakumu M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kentaro Yoshioka M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akinori Tsubouchi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shinichi Kakumu M.D..

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kakumu, S., Yoshioka, K. & Tsubouchi, A. Antibody to liver-specific lipoprotein in acute and chronic liver diseases. its quantitative assay with monoclonal antibody, but without the use of liver-specific lipoprotein. Gastroenterol Jpn 20, 216–221 (1985). https://doi.org/10.1007/BF02774707

Download citation

Key words

  • Serum antibody to liver-specific lipoprotein
  • Liver disease
  • RIA with monoclonal antibody